{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:44Z","timestamp":1782337244731,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011353","name":"Center for Clinical and Translational Science, University of Massachusetts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001453"],"award-info":[{"award-number":["UL1TR001453"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002618","name":"Aplastic Anemia and MDS International Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008523","name":"Center for Clinical and Translational Science, University of Illinois at Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.leukres.2024.107519","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T15:14:09Z","timestamp":1715440449000},"page":"107519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Translational insights into the genetics and immunobiology of relapsed\/refractory follicular lymphoma"],"prefix":"10.1016","volume":"142","author":[{"given":"Benyamin","family":"Yaniv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tanenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kazakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107519_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2024.107519_bib3","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression","volume":"124","author":"Sungalee","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.leukres.2024.107519_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib6","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107519_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00598-x","article-title":"Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107519_bib9","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-8722-2-14","article-title":"R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature","volume":"2","author":"Siddhartha","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib13","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2024.107519_bib15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2024.107519_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107519_bib18","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107519_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2021-145025","article-title":"Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed\/Refractory Follicular Lymphoma (r\/r FL): Subgroup Analysis of the Phase II Elara Study","volume":"138","author":"Thieblemont","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.leukres.2024.107519_bib23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (Liso-cel) in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib26","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2024.107519_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2024.107519_bib29","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib30","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107519_bib31","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107519_bib32","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv."},{"issue":"33","key":"10.1016\/j.leukres.2024.107519_bib33","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib34","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107519_bib36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107519_bib37","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.leukres.2024.107519_bib38","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2023.41.16_suppl.7506","article-title":"Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status","volume":"41","author":"Merryman","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107519_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib40","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA Study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma comparable to autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.leukres.2024.107519_bib41","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib42","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial.","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.leukres.2024.107519_bib43","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107519_bib44","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood-2023-178825","article-title":"Limited duration loncastuximab tesirine with rituximab induces high complete metabolic response rate in high-risk relapsed\/refractory follicular lymphoma - a phase 2 study","volume":"142","author":"Alderuccio","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fonc.2018.00219","article-title":"Cancer Immunotherapy and the Immune Response in Follicular Lymphoma","volume":"8","author":"Stenner","year":"2018","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107519_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/asheducation-2018.1.194","article-title":"Novel immunotherapy approaches to follicular lymphoma","author":"Flowers","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2024.107519_bib47","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1182\/blood-2011-11-367730","article-title":"Follicular lymphoma and the immune system: from pathogenesis to antibody therapy","volume":"119","author":"Stevenson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107519_bib48","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107519_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3164_174","article-title":"The Immunobiology of histologic transformation in follicular lymphoma: a multi-omic case-control study","author":"Soekojo","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2024.107519_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.19001","article-title":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","volume":"203","author":"Gao","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T23:43:36Z","timestamp":1720223016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"alternative-id":["S0145212624000857"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107519","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational insights into the genetics and immunobiology of relapsed\/refractory follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107519"}}